Front. Endocrinol.Frontiers in EndocrinologyFront. Endocrinol.1664-2392Frontiers Media S.A.10.3389/fendo.2025.1631601EndocrinologyCorrectionCorrigendum: Biomarkers of GH deficiency identified in untreated and GH-treated Pit-1 mutant miceAl-SamerriaSarmed1*XuHuiting2Diaz-RubioM. Elena3PhelanJoseph2SuChi2MaKeer2NewenAnna2LiKiana2YamadaSayaka4NegronAriel L.1WondisfordFredric4RadovickSally11Department of Pediatrics, University of Arizona College of Medicine, Phoenix, AZ, United States2Department of Medicine, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States3Rutgers Cancer Institute, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States4Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, United States
Edited and Reviewed by: Nienke Biermasz, Leiden University, Netherlands
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on Biomarkers of GH deficiency identified in untreated and GH-treated Pit-1 mutant mice By Al-Samerria S, Xu H, Diaz-Rubio ME, Phelan J, Su C, Ma K, Newen A, Li K, Yamada S, Negron AL, Wondisford F and Radovick S (2025) Front. Endocrinol. 16:1539797. doi: 10.3389/fendo.2025.1539797growth hormone deficiency (GHD)biomarkersPIT-1 mutationmetabolomicsGH treatmentenergy metabolismsex differencesNational Institute for Health Care Management Foundation10.13039/100014261section-in-acceptancePituitary Endocrinology
There was a mistake in Figure 5 as published. Figure 5 was incorrect and mistakenly showed the same content as Figure 6, rather than the correct figure. The corrected Figure 5 and its caption appear below.
Comparative metabolomic analysis to identify GHD Biomarkers in male mice. This figure examines metabolomic profiles under different GH conditions to identify GHD biomarkers and GH treatment effects. PCA plots (a–c) show metabolic distinctions: (a) GH sufficient (WT) vs. GHD (Mut), (b) GHD (Mut) vs. GH supplemented (Mut + GH), and (c) GH sufficient (WT) vs. GH excess (WT + GH). Volcano plots (d–f) display differentially expressed metabolites based on Log2 fold change and p-values for the same comparisons. Heatmaps (g–i) illustrate key metabolite expression across groups.
The image contains nine panels of metabolomic data visualizations. Panels (a), (b), and (c) are principal component analysis (PCA) plots comparing metabolic profiles among wild-type (WT), mutant (Mut), and GH-treated groups in male mice. Panels (d), (e), and (f) are volcano plots displaying differentially expressed metabolites, with the x-axis showing log₂ fold change and the y-axis showing –log₁₀(p-value). Panels (g), (h), and (i) are heatmaps depicting metabolite expression across experimental groups, using color gradients to indicate relative abundance. Each panel is labeled for clarity.
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.